Shay is a seasoned technology entrepreneur previously co-founding and serving as CEO of four companies: Seruus Telecom Fund, L.P. (1996), Trivergent (Nuvox) Communications (1997), UCI Communications (2003), and Green Cloud Technologies (2011). His expertise is creating recurring revenue-based services that are sold to enterprises and distributed through channel partners. Shay has significant experience raising capital (raised over $275mm through 30 transactions and filed for an IPO) and he has sourced and closed 20+ acquisitions. Shay is a 3x Inc. 500/5000 award winner from 2015-2017 with his time as CEO of Green Cloud Technologies. He is a graduate of The Citadel and serves on the business advisory board for The Citadel’s Baker School of Business. He is also in recovery and fueled by a passion to help others.
Richard Hanbury is the founder and CEO of Sana Health, an audiovisual technology allowing individuals to accelerate physical recovery and improve mental well-being to achieve a more restful state of mind. In 1992, Richard Hanbury survived a near fatal car accident, causing extreme nerve damage and leaving him with five years to live. Suffering in chronic pain, Richard began to experiment with the different neuromodulation patterns and bio-metric sensors to normalize his brain processed pain signals. His earliest prototype of Sana Health’s device successfully removed his nerve damage pain, and he has been pain-free since 1993. Richard is a former McKinsey associate and co-founded the estate agency software system, Easymatch. He received his MBA from Wharton in Healthcare and Entrepreneurial Studies and diploma in law CPE from College of Law
Marisa Barbieri is the CEO and Digital Health Solutions Architect at Competitive Solutions, a healthcare technology company based in New York, with over 20 years of healthcare IT technology solutions experience in the consulting industry. At Competitive Solutions, she has designed and developed PeerRX, a tool to accelerate and streamline peer support deployment for substance user disorder patients in order to increase peer recovery engagement. Marisa developed the product in direct response to the loss of a family friend from an overdose. After seeing him struggle as a young 27-year old, she saw the need for the development of an Uber-like technology to connect those battling with addiction to other survivor peers. PeerRX was born 2 years following her family friend’s death, in his memory, and with the hope of saving the lives of others struggling with substance use disorder. Marisa holds an MS in Computer Science / Telecommunications Management from NYU’s Polytechnic School of Engineering.
Dr. Maya Said is the founder and CEO of Outcomes4Me, a health technology company focused on providing patients diagnosed with cancer and other chronic diseases with personalized treatment options as well as outcomes information. She currently serves on the Board of Directors of two immune-focused biotech companies, Transgene and Pieris Pharmaceuticals. She was the COO of Celsius Therapeutics, an autoimmune disease and cancer-focused biotech company, where she established and managed the company’s operations from inception through the company’s first year post-launch. Prior to founding Outcomes4Me, Maya held senior leadership positions at pharmaceutical companies, Novartis and Sanofi, the Boston Consulting Group, as well as research positions at MIT.. As SVP and Global Head Oncology Policy and Market Access at Novartis, she drove the overall worldwide strategy and operations for the Novartis oncology business on pricing, market access, stakeholder engagement and other areas related to patients’ access to Novartis oncology products including the creation of payer-relevant clinical, real world and economic evidence. At Sanofi, Maya served as the VP and Head of Global R&D Strategy, External Innovation and Science Policy, playing a key role in establishing Sanofi’s new R&D model and open innovation approach. Maya has authored numerous scientific and strategy publications and has received several awards. Maya earned her BS in Biology and in Electrical Engineering and Computer Science, MS in Toxicology, MEng in Electrical Engineering and Computer Science, and ScD in Electrical Engineering, Computer Science and Systems Biology at MIT.
Dr. Øystein Rekdal is the co-founder and CEO of Lytix Biopharma, a clinical stage biotechnology company developing oncolytic peptides with the potential to personalize immunotherapy. Øystein has an extensive research background in tumor immunology and oncolytic peptides. His personal connection to cancer lies in his grandfather who was diagnosed and operated on for a solid cancer in his stomach. Øystein received his PhD from UiT – The Arctic University of Norway in cytokines and tumor immunology. After his PhD, Øystein was trained in Peptide synthesis technologies at Centre National de la Recherche Scientifique, in Strasbourg and followed a course at Harvard Medical School, Boston termed, “Tumor Microcirculation, Angiogenesis and Metastasis” His postdoctoral work furthered research on oncolytic peptides and their abilities to induce potent tumor specific immune responses. Øystein has a visiting professor position at UiT, where he teaches about innovation in biomedicine. He has also completed a Norwegian leadership development program called “Leadership in front
Dr. Gilles Pagès is the chief scientific officer of Roca Therapeutics / InfAngioPharma, a biotechnology company focused on personalized prognosis and therapeutic solutions to cancer. Gilles is the director of
research at French National Institute of Health and Medical Research (INSERM) and consultant for the Scientific Center of Monaco (CSM). Gilles has received several international awards, published 150 papers,
authored 10 patents and participated in three clinical trials. Gilles obtained his PhD in molecular biology from the University of Nice.
Bob Manning is an experienced entrepreneur and the CEO at CureMatch, biotechnology digital health company focused on personalized medicine and combination therapy in oncology by using molecular profiles to determine the best treatment options for cancer patients. Bob has 20 years of experience in technology and health care, including medical device, IT and services. He is an expert at delivering products to the market and executing on business strategy. As co-founder of TruMed Systems, he transformed the way that physician offices manage and store vaccines, preserving efficacy and reducing disease outbreaks. He holds three patents from his work there. While at CareFusion he was an innovator in hosting PHI and HIPAA governed data, creating an analytics platform that generated millions in new incremental revenue. Bob has additionally worked at SAP, IBM, Teradata and Parametric Technology. Bob holds a BS from the University of Massachusetts and an MBA from Babson College.
Russell LaMontagne is the CEO of Boston Immune Technologies and Therapeutics, a biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases. Russell has 20 years of experience in the health care industry, primarily focusing on consulting roles at biotechnology companies and non-profits from the University of Pennsylvania and the New England Journal of Medicine to VIRxSYS and Bristol-Myers Squibb. Over the past ten years, Russell has organized partnerships with Massachusetts General Hospital to promote clinical trials and new indications for the BCG vaccine. Prior to co-founding Boston Immune Technologies and Therapeutics, Russell served as president of Corinth Group, a boutique healthcare consultancy. Russell received his BS in Biology from the University of Massachusetts at Amherst and his MS from Yale University.
Dr. Alexander Börve is the founder and CEO of First Derm, an on demand tele-dermatology service providing skin assessments to users in over 160 countries. First Derm’s technology provides people the ability to submit pictures using smartphones of skin concerns for quick assessments from dermatologists. Prior to founding First Derm, Alexander practiced as a specialist doctor in orthopaedic surgery at Sahlgrenska University Hospital in Gothenburg, Sweden. He was a part of the spine team and a tutor to medical students. Alexander moved to the Bay Area to attend the School of Public Health, UC Berkeley as a visiting PhD candidate. His thesis focused on digital health and has thus far published 4 peer reviewed scientific papers. His development of teledermatology in 2013 was used in his academic research group. The platform has won numerous prizes in digital health services and is a focal point in his on-going research in the field.
An early diagnosis of MS at 16 led Conor to gear his studies towards human nutrition, receiving his undergraduate degree at Trinity College, Dublin and PhD at University College, Dublin, School of Medicine. Conor has worked in several hospitals, universities and medical centers in Dublin, Washington DC and Australia. Initially returning to Ireland to pursue a lecturing role, Conor shifted his focus towards launching Setanta Nutrition, a natural, research-based, plant-based, whole-food product line to prevent and treat common diseases affecting brain health such as MS, Dementia, Alzheimer, and Parkinson. Conor has gained national recognition for his research, including winning Ireland’s Best Young Entrepreneur and raising pre-seed funding to further develop Setanta Nutrition.